公开(公告)号：US10188642B2

公开(公告)日：2019-01-29

申请号：US15852639

申请日：2017-12-22

Applicant: Cancer Research Technology Limited

Inventor： Swen Hoelder ,  Julian Blagg ,  Kwai-Ming Jack Cheung ,  Butrus Atrash ,  Peter Sheldrake

IPC: A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/541 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  A61K31/4375 ,  A61K31/4725 ,  A61K31/4747 ,  A61K31/4985 ,  A61K31/5355 ,  C07D491/107

Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

公开(公告)号：US20180117032A1

公开(公告)日：2018-05-03

申请号：US15852639

申请日：2017-12-22

Applicant: Cancer Research Technology Limited

Inventor： Swen Hoelder ,  Julian Blagg ,  Kwai-Ming Jack Cheung ,  Butrus Atrash ,  Peter Sheldrake

IPC: A61K31/4725 ,  C07D491/107 ,  A61K31/4375 ,  C07D471/04 ,  C07D417/14 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14 ,  C07D401/12 ,  C07D401/04 ,  A61K31/541 ,  A61K31/5355 ,  A61K31/519 ,  A61K31/506 ,  A61K31/4985 ,  A61K31/496 ,  A61K31/4747 ,  C07D487/04

CPC classification number: A61K31/4725 ,  A61K31/4375 ,  A61K31/4747 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5355 ,  A61K31/541 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/107

Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.